Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Please indicate which comment is of concern and why. Your comments will be sent to our moderator for review.

Report comment to moderator

MandatoryRequired fields.


How the RPS helped make FMD 'fit for purpose in the UK'


In what capacity have the RPS made FMD 'fit for purpose' for the UK, the go to organisation for all FMD matters have been the UK FMD WG which I have chaired on behalf of the NPA, which has all stakeholder for the FMD including the DH and MHRA, RPS are not there. SecureMed the stakeholder group which are responsible for creating the UK Hub for FMD, the NPA /CCA are directors of this, the RPS are not. When the Delegated Regulation was debated in the European Parliament, the NPA not only met with the commission it also met the DH and MHRA in order to affect the directive, we had no input from RPS, so how exactly have the RPS made the FMD 'fit for purpose' It is easy to take credit away from organisations and companies that have stood by their members to ensure implementation is effective and seamless, it is even easier to take credit for other organisations diligence and perseverance for the issue, what is difficult is put on record how you have delivered the outcome. I am disappointed the RPS feel they have got us this far, themselves!!!

Posted date

12 DEC 2017

Posted time



Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.